Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle loss linked to immunotherapy response in lung cancer

NCT ID NCT07192926

Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looked at 115 adults with advanced non-small cell lung cancer to see if muscle loss (sarcopenia) and a blood-based score called CTI affect how well immunotherapy works. Researchers reviewed medical records to measure muscle on CT scans and calculate CTI from routine blood tests. The goal is to find simple markers that could help doctors predict which patients will benefit most from treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

155 people

The number who actually took part.

Started

Dec 2022

Finished

Jun 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population comprised 155 adult patients with histologically confirmed metastatic non-small cell lung cancer (mNSCLC) who initiated immune checkpoint inhibitor (ICI)-based therapy at Ankara Etlik City Hospital between December 2022 and March 2025. All included patients had available baseline clinical and laboratory data, including the variables required to calculate the C-reactive protein-triglyceride glucose index (CTI) and cachexia index (CXI), as well as an eligible abdominal computed tomography scan obtained within 30 days before ICI initiation for L3-level body composition assessment. Longitudinal body composition analyses were conducted in a landmark cohort of 140 patients who also underwent an early follow-up CT assessment 8-12 weeks after ICI initiation and were alive and progression-assessable at the landmark time point.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Histologically confirmed diagnosis of metastatic non-small cell lung cancer (mNSCLC). * Received at least one cycle of immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) as part of routine clinical care. * Availability of baseline CT imaging (within 4 weeks before treatment initiation) and follow-up CT imaging at approximately 3 months. * Availability of baseline laboratory data including C-reactive protein (CRP), triglycerides, and fasting glucose. * Adequate clinical records for evaluation of treatment response and survival outcomes. Exclusion Criteria: * Age \<18 years. * Patients without immunotherapy treatment. * Incomplete or missing CT imaging or laboratory data required for sarcopenia or CTI assessment. * Patients lost to follow-up before first radiological evaluation. * Prior malignancy within 5 years (except adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 neoplasm non-small cell lung carcinoma Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic non-small cell lung cancer Neoplasm

Contacts and locations

Locations

  • Etlik City Hospital Medical Oncology Department

    Ankara, Yenimahalle, 06270, Turkey (Türkiye)

  • Etlik City Hospital Radiology Department

    Ankara, Yenimahalle, 06270, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.